The COVID-19 pandemic posed, and still poses, unprecedented challenges on all stages of clinical trials. Regulatory agencies published guidance on how to manage clinical trials, stating that priority was to be given to COVID-19 studies, slowing down and halting non-COVID-19 trials.
The pandemic has forced all stakeholders to think outside the box and beyond their comfort zone. Both our Clinical Pharmacology Unit and Clinical Operations will provide insights on how they handled this unforeseen situation. They will discuss why it is important to be flexible and learn quickly in order to be able to (re)start trials under implementation of a strict COVID-19 risk mitigation plan to minimize viral spread and impact on safety or data quality.
Join our presentation on 'The Impact of the COVID-19 pandemic on early phase clinical trials' during this 4-day webcast series on the latest clinical developments, innovations and collaborations.
For further information, please contact:
t: +32 (0) 15 27 32 50